Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations

Rotigotine (RTG) is a dopamine agonist that is used as mono and adjunct therapy to treat Parkinson’s disease, and as therapy for moderate-to-severe restless legs syndrome. RTG is the only dopamine agonist currently available as a 24-hour/day transdermal system, providing once-a-day dosing. As a tran...

Descripción completa

Detalles Bibliográficos
Autores principales: Kesayan, Tigran, Shaw, Jessica D, Jones, Tracy M, Staffetti, Joseph S, Zesiewicz, Theresa A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337197/
https://www.ncbi.nlm.nih.gov/pubmed/32669913
http://dx.doi.org/10.2147/DNND.S37268
_version_ 1783554462436032512
author Kesayan, Tigran
Shaw, Jessica D
Jones, Tracy M
Staffetti, Joseph S
Zesiewicz, Theresa A
author_facet Kesayan, Tigran
Shaw, Jessica D
Jones, Tracy M
Staffetti, Joseph S
Zesiewicz, Theresa A
author_sort Kesayan, Tigran
collection PubMed
description Rotigotine (RTG) is a dopamine agonist that is used as mono and adjunct therapy to treat Parkinson’s disease, and as therapy for moderate-to-severe restless legs syndrome. RTG is the only dopamine agonist currently available as a 24-hour/day transdermal system, providing once-a-day dosing. As a transdermal patch, RTG bypasses the gastrointestinal tract, making it a treatment option for patients with dysphagia. The use of RTG also avoids the need to schedule administration of medication around meals. This review provides a critical appraisal of RTG as treatment of Parkinson’s disease and RLS.
format Online
Article
Text
id pubmed-7337197
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73371972020-07-14 Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations Kesayan, Tigran Shaw, Jessica D Jones, Tracy M Staffetti, Joseph S Zesiewicz, Theresa A Degener Neurol Neuromuscul Dis Review Rotigotine (RTG) is a dopamine agonist that is used as mono and adjunct therapy to treat Parkinson’s disease, and as therapy for moderate-to-severe restless legs syndrome. RTG is the only dopamine agonist currently available as a 24-hour/day transdermal system, providing once-a-day dosing. As a transdermal patch, RTG bypasses the gastrointestinal tract, making it a treatment option for patients with dysphagia. The use of RTG also avoids the need to schedule administration of medication around meals. This review provides a critical appraisal of RTG as treatment of Parkinson’s disease and RLS. Dove 2015-07-03 /pmc/articles/PMC7337197/ /pubmed/32669913 http://dx.doi.org/10.2147/DNND.S37268 Text en © 2015 Kesayan et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
spellingShingle Review
Kesayan, Tigran
Shaw, Jessica D
Jones, Tracy M
Staffetti, Joseph S
Zesiewicz, Theresa A
Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
title Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
title_full Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
title_fullStr Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
title_full_unstemmed Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
title_short Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
title_sort critical appraisal of rotigotine transdermal system in management of parkinson’s disease and restless legs syndrome – patient considerations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337197/
https://www.ncbi.nlm.nih.gov/pubmed/32669913
http://dx.doi.org/10.2147/DNND.S37268
work_keys_str_mv AT kesayantigran criticalappraisalofrotigotinetransdermalsysteminmanagementofparkinsonsdiseaseandrestlesslegssyndromepatientconsiderations
AT shawjessicad criticalappraisalofrotigotinetransdermalsysteminmanagementofparkinsonsdiseaseandrestlesslegssyndromepatientconsiderations
AT jonestracym criticalappraisalofrotigotinetransdermalsysteminmanagementofparkinsonsdiseaseandrestlesslegssyndromepatientconsiderations
AT staffettijosephs criticalappraisalofrotigotinetransdermalsysteminmanagementofparkinsonsdiseaseandrestlesslegssyndromepatientconsiderations
AT zesiewicztheresaa criticalappraisalofrotigotinetransdermalsysteminmanagementofparkinsonsdiseaseandrestlesslegssyndromepatientconsiderations

Ejemplares similares